Veraxa Biotech shifts oncology R&D to FDA-aligned non-animal testing
Veraxa Biotech AG outlined an ESG-linked shift to FDA-aligned New Approach Methodologies (NAMs) to cut animal testing across its oncology R&D programs. The strategy targets faster clinical progress, lower development costs, shorter timelines and reduced reliance on non-human primate toxicology studies.